-
Mashup Score: 15
In adults with obesity or overweight without diabetes (type 1 or 2), individuals administered ecnoglutide had superior and sustained reduction in bodyweight versus placebo with a favourable safety profile, supporting its potential use for weight management.
Source: www.thelancet.comCategories: General Medicine NewsTweet
-
Mashup Score: 9
As is now well known, obesity and excess adiposity is a global health issue, burdening people with multiple comorbidities such as type 2 diabetes, cardiovascular disease, musculoskeletal diseases, cancer, and sleep apnoea.1 The treatment of obesity and its comorbidities has been revolutionised in the past 5–10 years with the introduction of GLP-1 receptor monoagonists such as semaglutide and, more recently, the GLP-1 and glucose-dependent insulinotropic peptide receptor multiagonist tirzepatide.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
@AmDiabetesAssn Comment: “GLP-1 and amylin receptor multiagonism with amycretin for obesity management” 🔗 https://t.co/pYFA7LthWr #ADA2025 @AmDiabetesAssn
-
-
Mashup Score: 12
In people with overweight or obesity, amycretin appeared safe and tolerable. Results from this first-in-human, phase 1 study support further investigation of the weight loss properties of amycretin.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
@AmDiabetesAssn “Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, randomised, placebo-controlled study” 🔗 https://t.co/iVjuGlYYw6 #ADA2025 @AmDiabetesAssn
-
-
Mashup Score: 12Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study - 16 hour(s) ago
In people with overweight or obesity, once-weekly subcutaneous amycretin up to 60 mg had a safety and tolerability profile consistent with GLP-1 and amylin agonists. Although a high frequency of gastrointestinal events was reported, rates were similar to those seen in early-phase studies of these molecules. These results support further investigation into the weight loss properties of amycretin.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
“Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: Results of a randomised, controlled, phase 1b/2a study” 🔗 https://t.co/kHePt6yezD #ADA2025 @AmDiabetesAssn
-
-
Mashup Score: 14Highlights 2025 photography competition: illuminating health stories in a single frame - 16 hour(s) ago
In a single frame a photograph is a powerful way to tell a story and highlight an important issue. Each year The Lancet invites submissions for the Highlights photography competition and since 2009 we have published photographs from many countries that tell diverse health stories. Last year winning pictures portrayed aspects of health in both rural and urban settings and came from countries such as Cambodia, India, Japan, Kenya, Lesotho, Nepal, the UK, and Ukraine.1
Source: www.thelancet.comCategories: General Medicine NewsTweet-
Our annual #LancetHighlights photography competition is now open for submissions. 📸 If you've taken a photo that captures a powerful health story, we want to see it. Find out more & enter today: https://t.co/nMFFmnqqIg https://t.co/8nD1rm1ix7
-
-
Mashup Score: 19Moving the dial on diagnostics: an update from the Lancet Commission on diagnostics - 19 hour(s) ago
The Lancet Commission on diagnostics made recommendations for ten topics: national strategy (including national essential diagnostics lists), access in primary care, workforce, regulatory framework, national financing, affordability, appropriate use of technology, needs in conflict or fragile situations, advocacy, and an international alliance with oversight capabilities. Since 2021, progress in these areas has benefitted greatly from the adoption of a World Health Assembly resolution on diagnostics and the work of a broad coalition, as assessed by literature surveys by subject matter experts, quantitative findings (where feasible), and an anonymous survey of knowledgeable and engaged individuals.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
In 2021, the Lancet Commission on diagnostics made 10 recommendations to reverse the huge gap in access to even the most basic diagnostics. A recent Review provides an update on the progress in transforming access to diagnostics: https://t.co/3vQe5DfXSj https://t.co/775sxAFog9
-
-
Mashup Score: 31The 2025 Wakley Prize: changing practice - 2 day(s) ago
Life, as philosopher Søren Kierkegaard put it, “must be understood backwards; but…it must be lived forwards”.1 Clinical experiences are often only fully understood in retrospect; but this year’s Wakley Prize gives you the opportunity to share your story for others to learn from as they move ahead in their personal and professional lives. We want to know what has sparked your curiosity, and what has changed as a result. This change could be on a personal level; it might relate to an individual patient; or it might concern the systems and structures that shape science and medicine.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
📢 We're now inviting submissions for our annual essay competition, the #WakleyPrize. Put pen to paper and share your thought provoking and original ideas about centring care in medicine. Find out more about this year’s theme and enter today: https://t.co/1DRCu4Cixa https://t.co/7WLEoC3Ra8
-
-
Mashup Score: 25The mpox response: African leadership, global responsibility - 2 day(s) ago
On June 9, WHO Director-General Tedros Adhanom Ghebreyesus announced that mpox would remain a public health emergency of international concern (PHEIC)—the highest level of alarm under international health law—following the advice of the International Health Regulations Emergency Committee. This announcement comes amid a surge of cases in Sierra Leone and the emergence of mpox in previously unaffected countries, including a first death in Ethiopia. The result has been not only fatalities, but also morbidities, complications, and the associated stigma.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
The mpox outbreak remains a global health emergency. Complex challenges, limited vaccine access, and inadequate testing hinder mpox control. Our latest Editorial highlights the need for urgent, coordinated action: https://t.co/FwWiL8vSkq https://t.co/sdv9SBam8x
-
-
Mashup Score: 15Femtech and women's health - The Lancet Voice - 3 day(s) ago
How safe is it to use period tracking and digital contraception apps? Who is your data being shared with? What regulation actually exists in this area to protect app users?Femtech offers women digital tools for tracking reproductive health. Gavin and Jessamy are joined by Dr. Catriona McMillan, Senior Research Fellow in Medical Law and Ethics at the University of Edinburgh, to talk about how accurate these apps actually are, significant concerns about data privacy, and what regulatory oversight exists and can be applied.
Source: www.buzzsprout.comCategories: General Medicine NewsTweet-
Femtech offers women digital tools for tracking reproductive health. Dr. Catriona McMillan joins our editors to talk about how accurate these apps actually are, significant concerns about data privacy, and regulatory oversight. 🔊 Listen now: https://t.co/IFkVl6YB0t
-
-
Mashup Score: 0Cancer vaccines and the future of immunotherapy - 3 day(s) ago
Vaccines have had a major impact on the control of infectious disease, most recently by helping to combat the COVID-19 pandemic. Prophylactic cancer vaccines have prevented several malignancies by protecting against cancer-causing pathogens. By contrast, therapeutic vaccines training the immune system to eliminate established tumours are now showing real promise in clinical settings. In the adjuvant setting, vaccines against melanoma and pancreatic cancer appear to be reducing minimal residual disease and relapse.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
Although the effect of vaccines on cancer has been modest, progress shows their potential to transform cancer outcomes. A new Review analyses the strengths & limitations of different vaccine approaches & discusses the next generation of cancer vaccines: https://t.co/brFQEgGfob https://t.co/Dg1j51DHeJ
-
📌 At #ADA2025 Ecnoglutide, a new medication for weight management, is a safe and effective, trial confirms. Read in @TheLancetEndo 👉 https://t.co/vDCXDdMxDZ @AmDiabetesAssn